Check Cap Ltd (CHEK) Raised to “Sell” at ValuEngine

Check Cap Ltd (CHEK) Raised to “Sell” at ValuEngine

Check Cap Ltd (NASDAQ:CHEK) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday.

A number of other brokerages have also issued reports on CHEK. Zacks Investment Research upgraded shares of Check Cap from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a research note on Thursday. Maxim Group restated a “buy” rating on shares of Check Cap in a research report on Tuesday. Finally, HC Wainwright set a $6.00 target price on shares of Check Cap and gave the stock a “buy” rating in a research report on Sunday, March 12th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $5.06.

Shares of Check Cap (NASDAQ:CHEK) traded down 0.93% during midday trading on Friday, reaching $1.98. The company’s stock had a trading volume of 11,478 shares. The stock’s market capitalization is $30.95 million. The company has a 50 day moving average of $2.07 and a 200-day moving average of $2.25. Check Cap has a 52 week low of $0.97 and a 52 week high of $3.42.

Check Cap (NASDAQ:CHEK) last announced its earnings results on Thursday, March 9th. The medical research company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.01. Equities research analysts predict that Check Cap will post ($0.62) earnings per share for the current year.

An institutional investor recently raised its position in Check Cap stock. Knott David M raised its stake in shares of Check Cap Ltd (NASDAQ:CHEK) by 1.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 162,871 shares of the medical research company’s stock after buying an additional 3,000 shares during the period. Knott David M owned approximately 1.05% of Check Cap worth $349,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 22.53% of the company’s stock.

Check Cap Company Profile

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CHEK”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

To view ValuEngine’s full report, visit ValuEngine’s official website.

Related posts

Leave a Comment